치매 치료 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global dementia treatment market size is expected to reach USD 41.24 Billion in 2034 from USD 21.01 Billion in 2025, growing at a CAGR of 7.78 during 2026-2034.This market is witnessing substantial growth as the global aging population continues to increase and the prevalence of dementia-related disorders rises. Dementia treatment includes pharmaceutical therapies, cognitive care programs, supportive medical services, and digital health solutions designed to improve patient outcomes and quality of life. Growing awareness of neurological disorders, improved diagnostic capabilities, and expanding healthcare access are encouraging earlier intervention and comprehensive disease management.

Pharmaceutical companies are investing heavily in research and development of innovative therapies targeting disease progression and symptom management. Advances in biomarker research, neuroimaging, and personalized medicine are improving diagnostic accuracy and supporting more effective treatment strategies. Governments and healthcare organizations are increasing investments in dementia awareness, caregiver support, and specialized healthcare services. Growing collaboration between research institutions and biotechnology companies continues accelerating therapeutic innovation.

The future outlook remains highly encouraging as scientific understanding of neurodegenerative diseases continues advancing. Artificial intelligence-assisted diagnostics, precision medicine, and novel biological therapies are expected to transform dementia care in the coming years. Expansion of community healthcare programs, digital monitoring technologies, and supportive care services will improve patient management. Continued research and healthcare investment will drive sustainable growth within the global dementia treatment market.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Indication

• Alzheimer's Disease Dementia
• Vascular Dementia
• Lewy Body Dementia
• Frontotemporal Dementia (FTD)
• Parkinson's Disease Dementia
• Others

By Drug Class

• Cholinesterase Inhibitors
• NMDA Receptor Antagonist
• MAO Inhibitors
• Combination Drug
• Others

By Route of Administration

• Oral
• Transdermal Patch
• Injectable

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

COMPANIES PROFILED

• Eisai Co. Ltd., Eli Lilly and Company, Novartis AG, Daiichi Sankyo, AbbVie Inc., Lundbeck, Biogen Inc., Cipla Ltd., Sun Pharmaceutical, Viatris Inc., F. Hoffmann-La Roche, Pfizer Inc., Johnson & Johnson (Janssen), Otsuka Pharmaceutical, Merz Therapeutics, TauRx Pharmaceuticals, Alzheon Inc., AC Immune SA, Cassava Sciences, Annovis Bio

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL DEMENTIA TREATMENT MARKET: BY INDICATION 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Indication
• 4.2. Alzheimer's Disease Dementia Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Vascular Dementia Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Lewy Body Dementia Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Frontotemporal Dementia (FTD) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Parkinson's Disease Dementia Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL DEMENTIA TREATMENT MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Drug Class
• 5.2. Cholinesterase Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. NMDA Receptor Antagonist Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. MAO Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Combination Drug Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL DEMENTIA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Route Of Administration
• 6.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Transdermal Patch Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Injectable Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL DEMENTIA TREATMENT MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Distribution Channel
• 7.2. Hospital Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Retail Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Online Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL DEMENTIA TREATMENT MARKET: BY REGION 2022-2034 (USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Indication
  • 8.2.2 By Drug Class
  • 8.2.3 By Route Of Administration
  • 8.2.4 By Distribution Channel
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Indication
  • 8.3.2 By Drug Class
  • 8.3.3 By Route Of Administration
  • 8.3.4 By Distribution Channel
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Indication
  • 8.4.2 By Drug Class
  • 8.4.3 By Route Of Administration
  • 8.4.4 By Distribution Channel
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Indication
  • 8.5.2 By Drug Class
  • 8.5.3 By Route Of Administration
  • 8.5.4 By Distribution Channel
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Indication
  • 8.6.2 By Drug Class
  • 8.6.3 By Route Of Administration
  • 8.6.4 By Distribution Channel
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL DEMENTIA TREATMENT INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Eisai Co. Ltd
  • 10.2.2 Eli Lilly And Company
  • 10.2.3 Novartis AG
  • 10.2.4 Daiichi Sankyo
  • 10.2.5 AbbVie Inc
  • 10.2.6 Lundbeck
  • 10.2.7 Biogen Inc
  • 10.2.8 Cipla Ltd
  • 10.2.9 Sun Pharmaceutical
  • 10.2.10 Viatris Inc
  • 10.2.11 F. Hoffmann-La Roche
  • 10.2.12 Pfizer Inc
  • 10.2.13 Johnson & Johnson (Janssen)
  • 10.2.14 Otsuka Pharmaceutical
  • 10.2.15 Merz Therapeutics
  • 10.2.16 TauRx Pharmaceuticals
  • 10.2.17 Alzheon Inc
  • 10.2.18 AC Immune SA
  • 10.2.19 Cassava Sciences
  • 10.2.20 Annovis Bio